Rigel Pharma (RIGL) Tops Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Rigel Pharma (RIGL) Tops Q3 EPS by 1c

Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update

November 6, 2018 4:01 PM EST

SOUTH SAN FRANCISCO, Calif., Nov. 6, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today reported financial results for the third quarter ended September 30, 2018, and also provided an update on the commercial launch of TAVALISSE for treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and its clinical development pipeline.

Recent Highlights

Net product sales of $4.9 million for TAVALISSE during the third quarter On October 29, entered into an exclusive license and supply agreement with Kissei... More